[Analysis of indoleamine 2, 3-dioxygenase expression in breast cancer patients with bone metastasis].

Kenichi Sakurai; Shigeru Fujisaki; Saki Nagashima; Tetsuyo Maeda; Masahiko Shibata; Kenshi Gonda; Ryouichi Tomita; Shuhei Suzuki; Yukiko Hara; Katsuhisa Enomoto; Sadao Amano

[Analysis of indoleamine 2, 3-dioxygenase expression in breast cancer patients with bone metastasis].

Kenichi Sakurai, Shigeru Fujisaki, Saki Nagashima, Tetsuyo Maeda, Masahiko Shibata, Kenshi Gonda, Ryouichi Tomita, Shuhei Suzuki, Yukiko Hara, Katsuhisa Enomoto, Sadao Amano

School of Medicine

Nihon University

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

We evaluated the clinical significance of indoleamine 2, 3-dioxygenase (IDO) expression in breast cancer patients with bone metastasis. IDO activity can be measured by the tryptophan(Trp)/kynurenine(Kyn) ratio. Trp and Kyn levels were measured by high-performance liquid chromatography (HPLC). The serum IDO levels of postoperative breast cancer patients with a high number of bone metastases were lower than those of patients with a single metastasis lesion. In addition, IDO activity increased in the cases in which the number of metastatic lesions to the bone increased. These results suggest that the expression of IDO in breast cancer patients with bone metastasis may play a critical role in immunosuppression in these patients.

Original language	English
Pages (from-to)	1776-1778
Number of pages	3
Journal	Japanese Journal of Cancer and Chemotherapy
Volume	39
Issue number	12
Publication status	Published - Nov 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{7c29dce838ec4173a87f4b08532135ae,

title = "[Analysis of indoleamine 2, 3-dioxygenase expression in breast cancer patients with bone metastasis].",

abstract = "We evaluated the clinical significance of indoleamine 2, 3-dioxygenase (IDO) expression in breast cancer patients with bone metastasis. IDO activity can be measured by the tryptophan(Trp)/kynurenine(Kyn) ratio. Trp and Kyn levels were measured by high-performance liquid chromatography (HPLC). The serum IDO levels of postoperative breast cancer patients with a high number of bone metastases were lower than those of patients with a single metastasis lesion. In addition, IDO activity increased in the cases in which the number of metastatic lesions to the bone increased. These results suggest that the expression of IDO in breast cancer patients with bone metastasis may play a critical role in immunosuppression in these patients.",

author = "Kenichi Sakurai and Shigeru Fujisaki and Saki Nagashima and Tetsuyo Maeda and Masahiko Shibata and Kenshi Gonda and Ryouichi Tomita and Shuhei Suzuki and Yukiko Hara and Katsuhisa Enomoto and Sadao Amano",

year = "2012",

month = nov,

language = "English",

volume = "39",

pages = "1776--1778",

journal = "Japanese Journal of Cancer and Chemotherapy",

issn = "0385-0684",

publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

number = "12",

}

TY - JOUR

T1 - [Analysis of indoleamine 2, 3-dioxygenase expression in breast cancer patients with bone metastasis].

AU - Sakurai, Kenichi

AU - Fujisaki, Shigeru

AU - Nagashima, Saki

AU - Maeda, Tetsuyo

AU - Shibata, Masahiko

AU - Gonda, Kenshi

AU - Tomita, Ryouichi

AU - Suzuki, Shuhei

AU - Hara, Yukiko

AU - Enomoto, Katsuhisa

AU - Amano, Sadao

PY - 2012/11

Y1 - 2012/11

N2 - We evaluated the clinical significance of indoleamine 2, 3-dioxygenase (IDO) expression in breast cancer patients with bone metastasis. IDO activity can be measured by the tryptophan(Trp)/kynurenine(Kyn) ratio. Trp and Kyn levels were measured by high-performance liquid chromatography (HPLC). The serum IDO levels of postoperative breast cancer patients with a high number of bone metastases were lower than those of patients with a single metastasis lesion. In addition, IDO activity increased in the cases in which the number of metastatic lesions to the bone increased. These results suggest that the expression of IDO in breast cancer patients with bone metastasis may play a critical role in immunosuppression in these patients.

AB - We evaluated the clinical significance of indoleamine 2, 3-dioxygenase (IDO) expression in breast cancer patients with bone metastasis. IDO activity can be measured by the tryptophan(Trp)/kynurenine(Kyn) ratio. Trp and Kyn levels were measured by high-performance liquid chromatography (HPLC). The serum IDO levels of postoperative breast cancer patients with a high number of bone metastases were lower than those of patients with a single metastasis lesion. In addition, IDO activity increased in the cases in which the number of metastatic lesions to the bone increased. These results suggest that the expression of IDO in breast cancer patients with bone metastasis may play a critical role in immunosuppression in these patients.

UR - http://www.scopus.com/inward/record.url?scp=84875911068&partnerID=8YFLogxK

M3 - Article

C2 - 23267883

AN - SCOPUS:84875911068

SN - 0385-0684

VL - 39

SP - 1776

EP - 1778

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

IS - 12

ER -

[Analysis of indoleamine 2, 3-dioxygenase expression in breast cancer patients with bone metastasis].

Abstract

UN SDGs

Other files and links

Fingerprint

Cite this